aspirin has been researched along with Degenerative Diseases, Central Nervous System in 8 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin was substantially more effective than salicylate in reducing or delaying aggregation in human neuroblastoma cells grown in vitro, and in Caenorhabditis elegans models of human neurodegenerative diseases in vivo." | 3.85 | Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation. ( Alla, R; Ayyadevara, S; Balasubramaniam, M; Kakraba, S; Mehta, JL; Shmookler Reis, RJ, 2017) |
| "Collectively, these findings highlight the combination of Docosahexaenoic Acid and Aspirin as a possible measure against inflammation of the nervous system, thus leading to protection against neurodegenerative diseases with an inflammatory etiology." | 3.79 | Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin. ( Pettit, LK; Tadros, J; Varsanyi, C; Vassiliou, E, 2013) |
| "Both metformin and aspirin have been associated with improved cognitive outcomes." | 2.72 | AMPK activators for the prevention and treatment of neurodegenerative diseases. ( Neumann, NR; Thompson, DC; Vasiliou, V, 2021) |
| "With aspirin there is a 1." | 2.42 | [Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?]. ( Martin-Du Pan, RC, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Neumann, NR | 1 |
| Thompson, DC | 1 |
| Vasiliou, V | 1 |
| Ayyadevara, S | 1 |
| Balasubramaniam, M | 1 |
| Kakraba, S | 1 |
| Alla, R | 1 |
| Mehta, JL | 1 |
| Shmookler Reis, RJ | 1 |
| Yi, X | 2 |
| Zhou, Q | 2 |
| Wang, C | 2 |
| Lin, J | 2 |
| Chai, Z | 1 |
| Ryan, JC | 1 |
| Cross, CA | 1 |
| Van Dolah, FM | 1 |
| Wang, F | 1 |
| Zhai, H | 1 |
| Huang, L | 1 |
| Li, H | 1 |
| Xu, Y | 1 |
| Qiao, X | 1 |
| Sun, S | 1 |
| Wu, Y | 1 |
| Pettit, LK | 1 |
| Varsanyi, C | 1 |
| Tadros, J | 1 |
| Vassiliou, E | 1 |
| Martin-Du Pan, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aspirin and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
AMPK activators for the prevention and treatment of neurodegenerative diseases.
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Enzyme Activators; Humans; Metformin; Momordica cha | 2021 |
[Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or vitamins?].
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Humans; Neurodegenerative Diseases; Vita | 2003 |
1 trial available for aspirin and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem | 2018 |
5 other studies available for aspirin and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation.
Topics: Acetylation; Animals; Aspirin; Caenorhabditis elegans; Cell Line; Disease Models, Animal; Humans; Mo | 2017 |
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.
Topics: Aged; Asian People; Aspirin; China; Cyclooxygenase 1; Cyclooxygenase 2; Drug Resistance; Female; Gen | 2017 |
Effects of COX inhibitors on neurodegeneration and survival in mice exposed to the marine neurotoxin domoic acid.
Topics: Animals; Aspirin; Cell Survival; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Administrat | 2011 |
Aspirin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity in primary midbrain cultures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Astrocytes; Coculture Techniques; Dopamin | 2012 |
Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin.
Topics: Anti-Inflammatory Agents; Aspirin; Cells, Cultured; Docosahexaenoic Acids; Glutathione; Humans; Infl | 2013 |